Multiple sclerosis in the context of the COVID-19 pandemic

Sergey M. Karpov; Irina A. Vyshlova; Anna I. Klimenko; Evgenii A. Tkachenko; Rustam N. Gadaborshev; Akhshar I. Dzutsev

doi:10.17816/nb115009

Neurology Bulletin ›› 2023, Vol. LV ›› Issue (1) :47 -53. DOI: 10.17816/nb115009

Reviews

review-article

Multiple sclerosis in the context of the COVID-19 pandemic

Author information +

History +

PDF (181KB)

Abstract

Multiple sclerosis is a serious, potentially disabling disease of the central nervous system that often affecting several areas of the brain and spinal cord at the same time. A large number of patients with this disease have been identified in Russia. The aetiology of multiple sclerosis is still under investigation. Every year, new data emerge on the influence of different factors and their interaction. Modern science is actively studying the mechanisms of multiple sclerosis progression, the role of mitochondria in inflammation and neurodegeneration, as well as the impact of COVID-19 on the possibility of development and progression of multiple sclerosis. In this review, we will consider the impact of the SARS-CoV-2 virus on the course of multiple sclerosis.

Keywords

multiple sclerosis / COVID-19 / SARS-CoV-2 / coronavirus infection

Cite this article

Download citation ▾

Sergey M. Karpov, Irina A. Vyshlova, Anna I. Klimenko, Evgenii A. Tkachenko, Rustam N. Gadaborshev, Akhshar I. Dzutsev. Multiple sclerosis in the context of the COVID-19 pandemic. Neurology Bulletin, 2023, LV(1): 47-53 DOI:10.17816/nb115009

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Zhou F, Yu T, Du R et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395(10229):1054–1062. DOI: 10.1016/s0140-6736(20)30566-3.

[2]	Zhou F., Yu T., Du R. et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: A retrospective cohort study // Lancet. 2020. Vol. 395. N. 10229. P. 1054–1062. DOI: 10.1016/s0140-6736(20)30566-3.

[3]	Guan WJ, Ni ZY, Hu Y et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. DOI: 10.1056/NEJMoa2002032.

[4]	Guan W.J., Ni Z.Y., Hu Y. et al. Clinical characteristics of coronavirus disease 2019 in China // N. Engl. J. Med. 2020. Vol. 382. N. 18. P. 1708–1720. DOI: 10.1056/NEJMoa2002032.

[5]	Popova EV, Aleksandrov MI, Trubnikova IA et al. Clinical observation of the course of COVID-19 in patients with multiple sclerosis on the background of therapy with ocrelizumab: Two clinical cases. Meditsinskii sovet. 2021;(10):108–111. (In Russ.) DOI: 10.21518/2079-701X-2021-10-108-111.

[6]	Попова Е.В., Александров М.И., Трубникова И.А. и др. Клиническое наблюдение течения COVID-19 у больных рассеянным склерозом на фоне терапии препаратом окрелизумаб: два клинических случая // Медицинский совет. 2021. №10. С. 108–111. DOI: 10.21518/2079-701X-2021-10-108-111.

[7]	Oh J, Vidal-Jordana A, Montalban X. Multiple sclerosis: Clinical aspects. Curr Opin Neurol. 2018;31(6):752–759. DOI: 10.1097/WCO.0000000000000622.

[8]	Oh J., Vidal-Jordana A., Montalban X. Multiple sclerosis: Clinical aspects // Curr. Opin. Neurol. 2018. Vol. 31. N. 6. P. 752–759. DOI: 10.1097/WCO.0000000000000622.

[9]	Yamout BI, Alroughani R. Multiple sclerosis. Semin Neurol. 2018;38(2):212–225. DOI: 10.1055/s-0038-1649502.

[10]	Yamout B.I., Alroughani R. Multiple sclerosis // Semin. Neurol. 2018. Vol. 38. N. 2. P. 212–225. DOI: 10.1055/s-0038-1649502.

[11]	Doshi A, Chataway J. Multiple sclerosis, a treatable disease. Clin Med (Lond). 2016;16(6):53–59. DOI: 10.7861/clinmedicine.16-6-s53.

[12]	Doshi A., Chataway J. Multiple sclerosis, a treatable disease // Clin. Med. (Lond.). 2016. Vol. 16. N. 6. P. 53–59. DOI: 10.7861/clinmedicine.16-6-s53.

[13]	Dobson R, Giovannoni G. Multiple sclerosis — a review. Eur J Neurol. 2019;26(1):27–40. DOI: 10.1111/ene.13819.

[14]	Dobson R., Giovannoni G. Multiple sclerosis — a review // Eur. J. Neurol. 2019. Vol. 26. N. 1. P. 27–40. DOI: 10.1111/ene.13819.

[15]	Walton C, King R, Rechtman L et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020;26(14):1816–1821. DOI: 10.1177/1352458520970841.

[16]	Walton C., King R., Rechtman L. et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition // Mult. Scler. 2020. Vol. 26. N. 14. P. 1816–1821. DOI: 10.1177/1352458520970841.

[17]	The Multiple Sclerosis International Federation. Atlas of MS. 3rd ed. 2020. https://www.msif.org/wp-content/uploads/2020/12/Atlas-3rd-Edition-Epidemiology-report-EN-updated-30-9-20.pdf (access date: 15.11.2022).

[18]	Howard J, Trevick S, Younger DS. Epidemiology of multiple sclerosis. Neurol Clin. 2016;34(4):919–939. DOI: 10.1016/j.ncl.2016.06.016.

[19]	Howard J., Trevick S., Younger D.S. Epidemiology of multiple sclerosis // Neurol. Clin. 2016. Vol. 34. N. 4. P. 919–939. DOI: 10.1016/j.ncl.2016.06.016.

[20]	Garg N, Smith TW. An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis. Brain Behav. 2015;5(9):362. DOI: 10.1002/brb3.362.

[21]	Garg N., Smith T.W. An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis // Brain Behav. 2015. Vol. 5. N. 9. P. 362. DOI: 10.1002/brb3.362.

[22]	Ministerstvo zdravookhraneniia Rossiiskoi Federatsii. Clini-cal recommendations ‘Multiple sclerosis”. 2022. р. 195. (In Russ.) https://centrems.com/downloads/Clinical_recommendations_of_the_RS-Project_submitted_to_the_MHRF.pdf (access date: 15.11.2022).

[23]	Министерство здравоохранения Российской Федерации. Клинические рекомендации «Рассеянный склероз». https://centrems.com/downloads/Clinical_recommendations_of_the_RS-Project_submitted_to_the_MHRF.pdf (дата обращения: 15.11.2022).

[24]	Steinman L, Fox E, Hartung HP et al. Ublituximab versus Teriflunomide in relapsing multiple sclerosis. N Engl J Med. 2022;387(8):704–714. DOI: 10.1056/NEJMoa2201904.

[25]	Steinman L., Fox E., Hartung H.P. et al. Ublituximab versus Teriflunomide in relapsing multiple sclerosis // N. Engl. J. Med. 2022. Vol. 387. N. 8. P. 704–714. DOI: 10.1056/NEJMoa2201904.

[26]	Damal K, Stoker E, Foley JF. Optimizing therapeutics in the management of patients with multiple sclerosis: A review of drug efficacy, dosing, and mechanisms of action. Biologics. 2013;7:247–258.

[27]	Damal K., Stoker E., Foley J.F. Optimizing therapeutics in the management of patients with multiple sclerosis: A review of drug efficacy, dosing, and mechanisms of action // Biologics. 2013. N. 7. P. 247–258.

[28]	Ghajarzadeh M, Bonavita S. Are patients with multiple sclerosis (MS) at higher risk of COVID-19 infection? Neurol Sci. 2020;41(9):2315–2316. DOI: 10.1007/s10072-020-04570-8.

[29]	Ghajarzadeh M., Bonavita S. Are patients with multiple sclerosis (MS) at higher risk of COVID-19 infection? // Neurol. Sci. 2020. Vol. 41. N. 9. P. 2315–2316. DOI: 10.1007/s10072-020-04570-8.

[30]	Landtblom AM, Berntsson SG, Boström I et al. Multiple sclerosis and COVID-19: The Swedish experience. Acta Neurol Scand. 2021;144(3):229–235. DOI: 10.1111/ane.13453.

[31]	Landtblom A.M., Berntsson S.G., Boström I. et al. Multiple sclerosis and COVID-19: The Swedish experience // Acta. Neurol. Scand. 2021. Vol. 144. N. 3. P. 229–235. DOI: 10.1111/ane.13453.

[32]	Safavi F, Nourbakhsh B, Azimi AR. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. Mult Scler Relat Disord. 2020;43:102–195. DOI: 10.1016/j.msard.2020.102195.

[33]	Safavi F., Nourbakhsh B., Azimi A.R. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran // Mult. Scler. Relat. Disord. 2020. N. 43. P. 102–195. DOI: 10.1016/j.msard.2020.102195.

[34]	Hada M, Mosholder AD, Leishear K et al. Systematic review of risk of SARS-CoV-2 infection and severity of COVID-19 with therapies approved to treat multiple sclerosis. Neurol Sci. 2022;43(3):1557–1567. DOI: 10.1007/s10072-021-05846-3.

[35]	Hada M., Mosholder A.D., Leishear K. et al. Systematic review of risk of SARS-CoV-2 infection and severity of COVID-19 with therapies approved to treat multiple sclerosis // Neurol. Sci. 2022. Vol. 43. N. 3. P. 1557–1567. DOI: 10.1007/s10072-021-05846-3.

[36]	Bsteh G, Bitschnau C, Hegen H et al. Multiple sclerosis and COVID-19: How many are at risk? Eur J Neurol. 2021;28(10):3369–3374. DOI: 10.1111/ene.14555.

[37]	Bsteh G., Bitschnau C., Hegen H. et al. Multiple sclerosis and COVID-19: How many are at risk? // Eur. J. Neurol. 2021. Vol. 28. N. 10. P. 3369–3374. DOI: 10.1111/ene.14555.

[38]	Sormani MP, De Rossi N, Schiavetti I et al. Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol. 2021;89(4):780–789. DOI: 10.1002/ana.26028.

[39]	Sormani M.P., De Rossi N., Schiavetti I. et al. Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis // Ann. Neurol. 2021. Vol. 89. N. 4. P. 780–789. DOI: 10.1002/ana.26028.

[40]	Salter A, Fox RJ, Newsome SD et al. Outcomes and risk factors associated with SARS-CoV-2 infection in a North Ameri-can Registry of patients with multiple sclerosis. JAMA Neurol. 2021;78(6):699–708. DOI: 10.1001/jamaneurol.2021.0688.

[41]	Salter A., Fox R.J., Newsome S.D. et al. Outcomes and risk factors associated with SARS-CoV-2 infection in a North American Registry of patients with multiple sclerosis // JAMA Neurol. 2021. Vol. 78. N. 6. P. 699–708. DOI: 10.1001/jamaneurol.2021.0688.

[42]	Kovvuru S, Nalleballe K, Onteddu SR et al. Immunosuppression in chronic autoimmune neurological disorders during the COVID-19 pandemic. J Neurol Sci. 2021;420:117–230. DOI: 10.1016/j.jns.2020.117230.

[43]	Kovvuru S., Nalleballe K., Onteddu S.R. et al. Immunosuppression in chronic autoimmune neurological disorders during the COVID-19 pandemic // J. Neurol. Sci. 2021. N. 420. P. 117–230. DOI: 10.1016/j.jns.2020.117230.

[44]	Hollen C, Bernard J. Multiple sclerosis management during the COVID-19 pandemic. Curr Neurol Neurosci Rep. 2022;22(8):537–543. DOI: 10.1007/s11910-022-01211-9.

[45]	Hollen C., Bernard J. Multiple sclerosis management during the COVID-19 pandemic // Curr. Neurol. Neurosci. Rep. 2022. Vol. 22. N. 8. P. 537–543. DOI: 10.1007/s11910-022-01211-9.